Expertise

Services

Solutions

About Us

Resources

Request Quote

20+ Years Of Bioanalysis
700+ Small/Large Molecule Studies
450+ Custom Bioanalytical Assays
200+ Investigational Drugs
1,000+ Biomarker & Cytokine Assays

What ELISA Assay Validation and Testing Services Do We Offer?

Advanced ELISA development, GLP validation, and lab services to accelerate PK/PD, ADA/nAb, cytokine analysis, and titration assays

ELISA Services for PK/PD, ADA/nAb, And Cytokine Analysis

  • Rigorous, GLP PK/ADA/nAb ELISA lab studies in rodents, large animals, and clinical trial samples
  • Quantitative Pharmacokinetics or Cytokine evaluation in plasma/serum, urine, CSF, cell lysates, and tissue homogenates

PK ELISA Method Development, Troubleshooting & Validation

  • Sensitive, selective, and specific ELISA PK assay for antibodies (MAbs, ADCs), proteins, oligonucleotides, etc.
  • Ligand‑binding (direct, indirect, sandwich, competitive) or hybrid ELISA PK assay method tailored to your drug and study

Custom ADA and  NAb Biological Assay Development

  • Free‑drug‑tolerant, three‑tiered ADA assay (bridging, acid dissociation, ACE, SPEAD, etc.) for biologics and cell therapies
  • Neutralizing Antibody Testing via competitive ligand-binding or cell-based ELISA platforms

Ultra-sensitive Cytokine Analysis using MSD Kits

  • S‑PLEX MSD cytokine assay detecting single or multiple biomarkers at femtogram per mL concentrations
  • Meso Scale ELISA CRO services quantitating cytokines, chemokines, or growth factors in small‑volume samples

Preclinical (GLP) & Clinical (GCP) ELISA Validation Services

  • Fit-for-Purpose (FFP) Validation aligned with FDA GLP/GCLP bioanalytical guidance and context-of-use requirements
  • Highly sensitive, validated ELISA method with a broad dynamic range despite typical clinical‑sample limitations

PD Biomarker Evaluation & ELISA Development

  • MOA-Confirming Immunoassays for pharmacodynamic (PD) biomarker verification
  • Analytical, Cellular, and Functional ELISAs for target identification, pathway interrogation, and validation

Cell-Based ELISA Testing for Potency, MOA & Cytotoxicity

  • Direct or indirect cell‑based ELISA in the presence/absence of therapeutic, ligand, or other stimulus
  • Functional bioassays for potency and quantitative cell‑based assays reflecting MOA (luciferase or MTT systems)

ELISA for Viral & Antibody Titer Quantification

  • AAV & Lentiviral Capsid ELISAs for capsid titration and protein quantification using proprietary or commercial reagents
  • Multiplexed Antibody-Titer Screening across diverse species and biological matrices to support immunogenicity and PK studies

Our ELISA Assay Validation Experts Have Deep & Diverse Experience With Enzyme-Linked Immunoassay Technology And Applications!

Monoclonal Ab Therapeutics

De Novo ELISA, GLP Validation Across Multiple Species And Matrices

Tri-/Bi-Specific Antibody

Domain Specific Assays With Free vs. Bound Analysis For Structure, Function, Binding, PK, Immunogenicity

Antibody Drug Conjugate

High Sensitivity Total/Conjugated Antibody Assay For Preclinical Screening, Clinical Sample Analysis

Multiplex Cytokine Assay

Ultra-Sensitive Multiplex Assay In Clinical Or Preclinical Serum/Plasma, PBMC, Tissues Etc.

Plate-Based NAb Assay

Receptor Binding And Functional Inhibition Measurement in Plasma/Serum

Virus Neutralization

Feasibility, Development, And Human Serum Sample Analysis

Activity/ Potency Assay

Biological Activity Enzymatic Assay to Assess Compound Potency, Purity

Contact A Scientist With Your ELISA Based Assay Details

We’ll Contact You Within 1 Business Day

Comprehensive Suite of PK/PD, ADA/nAb, And Biomarker Assay ELISA Services To Exceed Your Expectations

Kick‑Start Your ELISA Testing At Our Agile Lab!

We’ll Reach Out Within 1 Business Day
  • Your ELISA Based Assays matter to us. Don’t allow any ELISA Services Laboratory CRO to gloss over hidden pitfalls that can delay the development of your next therapeutic.
  • You are in the industry to improve the standard of care. Having an extremely responsive and flexible ELISA Immunoassay Services lab at your disposition will tremendously expedite your drug development.
  • Your budget needs to be stretched. Our ELISA Method Development Services expertise will ensure that your get farther along the regulatory submission process without spending more.

20+

Years of ELISA Lab Services With Industry Leading Turnaround

450+

Custom Bioanalytical Methods Completed Within Budget

Expected Services Turnaround

We are thrilled to collaborate with your team and achieve our shared goals for your ELISA Method Development and Immunoassay Validation. We can develop and validate de novo ELISA PK/ADA or ELISA biomarker assays in six to eight weeks. Then, we can deliver your audited report with detailed documentation of ELISA Immmoassay Validation experiments in a few weeks. We constantly stretch your budget by combining our scientific experience, regulatory expertise, and operational excellence.

Requested Sponsor Input

We are eager to work with you on your ELISA Immunoassay project. We believe close communication is vital to success, and want to understand your needs and expectations in advance as much as possible. To help us prepare a detailed quote and timeline, please share additional information about your analyte(s), critical reagents and supplies, current and previous Enzyme Linked Immunoassay, study protocols, and sample sizes. Thank you for choosing us as your bioanalytical partner in cutting-edge science!

Reviews From Sponsors of Our ELISA Assay Validation And ELISA Assay Develpoment Services

President & CSO, Biotech

We found their integrity as refreshing as readiness to provide creative scientific input and high-quality data

Co-Founder, Biotech & University PI

NorthEast BioLab tremendously supported us in reproducing our critical lab discoveries for drug metabolism

VP, Development Operations

NorthEast BioLab’s scientists deliver high-quality data on time and within budget

VP, Biomarker Development 

NorthEast BioLab is a responsive, collaborative, and reliable partner

Sr. Dir., Bioanalytical Development & QC

NorthEast BioLab offers a science-based, hands-on approach to the latest bioanalytical platforms

Executive Director, Pharmacokinetics

We trust NorthEast BioLab to design and execute streamlined, impactful bioanalytical projects

Unlock Precision, ROI With Our ELISA Service Expertise!

We’ll Respond Within 1 Business Day

Efficiently Accelerate Enzyme Linked Immunoassay For Your PK, Immunogenicity, and Multiplexed ELISA Cytokine Analysis

Expert GLP ELISA Development & ELISA Validation Services

  • End-to-End Immunoassay Development: Three decades of GLP ELISA assay expertise to improve every critical parameter—antibody pairing, plate coating, signal amplification
  • Up-Front Technical & Regulatory Review: We dissect your current ELISA methods, data sets, and submission needs, then deliver a written SOW and timeline within 48 hours
  • In-House Reagent Tagging for Agility: Custom biotin, HRP, or fluorophore conjugation on-site boosts lot-to-lot consistency, giving you tighter CVs and wider dynamic range

Responsive ELISA Assay CRO with Tailored Lab Testing Services

  • Quick-Turn Flex Scheduling: Accelerated starts and adjustable timelines accommodate urgent ELISA PK, ADA, or cytokine studies without compromising quality
  • Direct Access to Senior Scientists: Real-time conversations for ELISA troubleshooting and method refinements keep potential issues from ever reaching the data table
  • Dual-Layer Quality Assurance: Redundant QC and comprehensive audit trails deliver robust, reproducible ELISA results regulators trust—every single run

ELISA Assay Development & Method Development: A Step-by-Step Guide

ELISA is a powerful tool for detecting and quantifying target analytes in complex biological samples. The primary principle of ELISA assay focuses on capturing or immobilizing the target antigen on…

Our Streamlined Process For On-Time Delivery Of Entire Scope Of Work Within Sponsor Budget

Why Choose Us As Your ELISA Testing Services Lab?

FDA Audited ELISA Assay Validation, ELISA Assay Development, Or GLP Sample Analysis Bioanalytical Lab!

Partner With Our ELISA Lab For Swift, Valuable Results!

We’ll Get Back to You Within 1 Business Day
  • FDA-Compliant ELISA Method Development And Validation For Ligand Binding And Cell-Based Assays.
  • GLP And Research ELISA Services For PK, Cytokine, And Immunogenicity Assays.
  • Preclinical And Clinical ELISA Analysis For PD Biomarkers, Potency, And Functional Bioassays.
  • Customized ELISA Services For Viral And Antibody Titers In Various Biological Samples.

Support Your Drug Innovation With Entire Suite OF BioAnalytical Services In Safe Hands Of Our Veteran Scientists

We Judiciously Invest In Our People, Solutions And Infrastructure, And Regularly Review Our Business Processes And Practices To Exceed Sponsor Expectations.

Related FAQs

Answers to additional ELISA Assay questions popular among our potential sponsors.

What is Enzyme Linked Immunosorbent Assay (ELISA) Method?

ELISA Method: Accurate and Flexible Analysis in 96 well plates

Enzyme Linked Immunosorbent Assay (ELISA Assay) method is a widely utilized immunoassay for quantitating and detecting proteins, hormones, peptides(through ELISA peptide), cytokines, antibodies, and other drugs along with their metabolites. ELISA Assay methods are effective in quantitatively detecting any molecule, or antigen, that can be ascertained by an antibody. For example, ELISA methods are used in pregnancy testing, infectious disease identification, and detection of cytokines, and soluble receptor proteins, etc. Due to the precision, sensitivity, assay speed, and ease of quantitation, ELISA method development is a common choice for several diagnostic and research applications.

While there are various formats of ELISA method, the most common is a sandwich ELISA method. In this format, the analyte whose concentration is to be measured is sandwiched in-between two antibodies that bind to a different region (epitopes) on the antigen. These antibodies are referred to as detection antibody and capture antibody. In this assay, the capture antibody is coated to a microtiter plate in a 96-well format. The antigen binds to the capture antibody, and a detection antibody is used to measure the analyte. The antibody is conjugated to an enzyme, typically horseradish peroxidase (HRP), and detected via catalysis of a substrate which yields a colored product. Spectrophotometry is used to monitor the colored product, and a standard curve is utilized for calculating the antigen concentration in the sample. When the antigen is small, or two antibodies that can simultaneously bind to the antigen are unavailable, then another variation of ELISA, termed competitive ELISA method is utilized using a single epitope.

It is notable that the ELISA method typically uses 96 microwell plates for parallel analysis of many samples, standards, and controls in a single experiment. The surface of these plates is treated with special absorbents such that the antigen or antibody can adhere properly. ELISA method offers increased sensitivity and specificity compared to other standard antibody-based assays. In ELISA method, the interactions with analyte or antibody occur through serial binding that is done to some solid surface such as polystyrene in the 96 microwell plates discussed above.

What is ELISA Method Development?

Step-by-step ELISA Method Development

Enzyme Linked Immunosorbent Assay or ELISA Method development is a complex task involving multiple sequential steps for the measurement of analyte concentration in a sample.

Plate Coating

Whenever an ELISA method is developed for any analyte, a surface attachment strategy is established first. Once the analyte is affixed to the surface of the plate, it is immobilized and helps with the sequential addition of other reagents and washing cycles in the next steps, without mixing. ELISA method is thus a solid-phase assay.

The process of immobilizing an antibody or antigen to the plate is essential, as the method of immobilization utilized is what determines the efficacy of the ELISA method. Many times, the immobilization may cause a conformational change in the analyte or antibody, preventing the detection antibody from binding. Thus, it is critical to immobilize the antibody or antigen while preserving its conformational structure.

Antibody and Antigen Pairs

The specificity and sensitivity of the assay are determined using a range of concentrations of antibody and/or antigen. The affinity of the detection antibody and sensitivity of the detection reagents corresponding to a specific antigen are principally responsible for defining the performance of an optimized ELISA method. Selection of the best capture and detection antibody is critical for effective assay development.

Detection

The antibodies which are labeled with an enzyme (detection antibodies) contribute to the signal output of this assay. Different types of enzymes can be utilized, such as alkaline phosphatase, horseradish peroxidase, etc., each of which produces a color upon reacting with their substrates. These colored products are detected with spectrophotometry, where the signal intensity is proportional to the amount of antigen in the microwell. Afterward, a standard curve along with positive and negative controls is used to quantify the amount of analyte within a given sample.

Which ELISA Assay Development Services do we Offer?

Extensive ELISA Method Development by NorthEast BioLab

NorthEast BioLab offers various client-centric ELISA assay development services.

Bioanalytical Assay ELISA Development and Validation

Proper ELISA method development and validation are critical for the accurate quantification of an analyte. NorthEast BioLab helps you select the right ELISA method format and develop a robust protocol for analysis. Our specialists optimize the assay by titrating various components to ensure accurate results.

Pharmacokinetics (PK) Studies

Our pharmacokinetic studies for quantitation of drug-responsive levels of a specific serum protein using ELISA protein assay development allow accurate and reliable pharmacokinetic data to help regulate dosage regimens.

Toxicokinetic (TK) Studies

As in pharmacokinetic studies, an ELISA method can be used in toxicokinetic studies to quantitate a drug or compound when administered at high dosage. TK studies allow estimation of the level of toxicity that can be produced by these drug compounds.

Biomarker Testing

ELISA method is hugely popular as a fundamental, cost-effective technique that offers high precision and broad dynamic range in addition to specificity, selectivity, and reliability for biomarker testing and quantitation.

Immunogenicity Testing Assay

An ELISA method can be used for immunogenicity testing. These studies are carried out to assess how drug exposure induces an immune response in the body of humans or other animals. It further evaluates how anti-drug antibodies (ADA) can affect immunogenicity.

Cell-Based Assay

Our scientists help clients with the successful execution of cell-based assays to assess the toxicity of the compounds and ensure reliable drug manufacturing. For example, we perform cytotoxicity testing and mechanism of action (MOA) assay to understand the biochemical reactions triggered by drug compounds.

Why Choose us for your ELISA Assay Validation?

Frictionless ELISA Method from scratch or validated Research Use Only (RUO) kits

At NorthEast BioLab, we ensure robust ELISA methods to quantify large molecule analytes such as biologics, proteins, and antibodies in your samples. As often as it takes, our veteran scientists with 30+ years experience discuss and study your ELISA method development and validation in depth. Our team continues without yielding until we have customized these assays per your requirement and satisfaction.

We encourage intensive collaboration between the client and our scientists for complete transparency throughout your study with us. NorthEast BioLab offers quick turnaround times, scalability, and flexibility, given our extensive experience with ELISA method development and a thorough understanding of the science behind it. We enable our clients to expedite drug approval through efficient assay development, validation, and optimization while maintaining 100% regulatory compliance.

ELISA Method, based on colorimetric or chemiluminescent reaction, is the best-in-class ligand binding assay (LBA) predominantly used for large molecule bioanalytical method development and sample analysis. Scientists and regulatory agencies widely trust the direct, indirect, sandwich, and competitive variants of ELISA Development and Method Validation for diverse PK, BA/BE, TK, Immunogenicity (ADA), and Biomarker testing. Our veteran team undertakes Enzyme Linked Immunosorbent Assay development from scratch using available antibodies, diluents, buffers, substrates, reagents, control matrices, as well as research use only (RUO) kits. NorthEast BioLab delivers research mode, and fully GLP validated ELISA Method and Assay Development at an unmatched turnaround and value to sponsors.

What is Enzyme Linked Immunosorbent Assay (ELISA) Method Development?

ELISA Method is an abbreviation for enzyme-linked immunosorbent assay, also called enzyme immunoassays (EIA). The fundamental principle used in ELISA method development is the use of antibodies to detect and quantify proteins, peptides (through ELISA peptide), hormones, or other small molecules in preclinical or clinical samples. In an ELISA method development, antigens are immobilized on solid support either directly or via the use of a capture antibody immobilized on the surface. Subsequently, we add a primary detection antibody. If the detection antibody binds to the analyte of interest, the complex can be directly detected and quantified by the chromogenic tag or a secondary enzyme-conjugated antibody. In our GLP ELISA lab, we typically perform method development, validation, and sample analysis in multi-well plates (96- or 384-wells) for capture antigen binding. This characteristic makes the ELISA Assay Method easy to perform on multiple samples simultaneously with excellent selectivity.

What are the various types of ELISA immunoassays?

ELISA immunoassays include a direct, indirect, sandwich, and competitive variants. In the direct ELISA method, an antigen is immobilized to the surface of a multi-well plate and detected with an antigen-specific antibody directly conjugated to HRP or another detection tag.

For an indirect ELISA assay, as with the direct ELISA method, an antigen is immobilized to the surface of the multi-well plate, but we need a two-step process for detection. The primary antibody binds to the antigen of interest, and then a secondary antibody labeled with a detection reagent is used for quantification. The sandwich ELISA method, the most widely used format, requires an antibody pair where each antibody is specific to a different epitope of the antigen. The first antibody, often called the capture antibody, is coated on the 96 well plate and binds to the analyte of interest. Once the unbound materials in the sample matrix get washed away, the second antibody conjugated with a detection tag quantitates the analyte. Competitive ELISA methods, often referred to as an inhibition ELISA assay or competitive immunoassays, measure the concentration of an antigen by detecting signal interference. We can adapt direct, indirect, or sandwich ELISA assays to the competitive format. Here, the antigen in the sample competes with a reference antigen pre-coated on a multi-well plate or added in the same plate wells. Consequently, lower concentrations of analyte produce a higher level of the signal. Some competitive ELISA assay, however, utilize a slightly different approach. These kits substitute a labeled antigen for the labeled antibody, but the principle of the ELISA protein assay remains the same.

Why is Sandwich ELISA method more sensitive?

In the Sandwich ELISA method, the specificity and selectivity offered by matched antibody pairs provide improved sensitivity and broad dynamic range. These ELISA assays require two antibodies, attaching with different epitopes on the same antigen, making them suitable for accurately isolating and quantitating antigens of interest within complex biological matrices such as plasma, serum, CSF, tissue lysates, etc. Furthermore, sandwich ELISA development and validation are highly adaptable. We can optimize various assay conditions for the antibody pairs (e.g., type of assay plates, coating/washing/dilution buffer, coating-detection concentration, calibration standard/quality control/sample preparation, incubation times, etc.) to meet/exceed our immunoassay validation and sample analysis acceptance criteria. One of the most significant challenges faced by sponsor or ELISA Lab working on sandwich ELISA method is narrowing down a proprietary/commercially available antibody pair that works well together for desired assay parameters.

What is the difference between Direct ELISA vs. Indirect ELISA method?

In our GLP ELISA Lab, we perform both direct and indirect ELISA method development that differ in their means of detection. In the direct ELISA assay, an antigen is immobilized to the surface of a multi-well plate and detected with an antigen-specific antibody directly conjugated to HRP or other detection molecules. For an indirect ELISA assay, as with the direct ELISA method, the antigen is immobilized to the surface of the multi-well plate, but we need a two-step process for detection. The primary antibody binds to the analyte of interest and the secondary antibody labeled with the detection agent is used for quantitation. Direct ELISA methods are simple to set up and have no cross-reactivity from a secondary antibody but may have poor sensitivity due to high background as all proteins in the sample bind the well surface and there is no signal amplification to read the antigen. Indirect ELISA methods offer signal amplification to improve sensitivity but are more challenging to set up and perform and may have cross-reactivity from the secondary antibody.

What are the advantages of i) Direct ELISA, ii) Indirect ELISA, iii) Sandwich ELISA, and iv) Competitive ELISA?

The principle of ELISA involves antigen detection via binding to specific antibodies that we can apply in various formats. Direct ELISA method offers the advantages of easy experimental setup and execution, saving on time and reagent costs, and minimize concerns around cross-reactivity since there is no secondary antibody. Disadvantages of the direct ELISA method are the potential for high background due to all proteins in the sample binding the plate. Also, the primary antibody must be conjugated, and there is no signal amplification for analyte detection.

Indirect ELISA methods allow for signal amplification since multiple secondary antibodies can bind to the primary antibody. Indirect methods are also adaptable, allowing us to use the same secondary antibody for several primary antibodies. Disadvantages of an indirect ELISA method are potential cross-reactivity to the secondary antibody and higher time and cost needs relative to the direct ELISA method.

Sandwich ELISA methods offer excellent specificity as they employ two distinct antibodies for capture and detection. These ELISA, however, can be difficult to develop since discovering two antibodies that recognize two different epitopes on the same target and work well together can at times be difficult.

We can modify any ELISA method to a competitive format with a reference antigen and appropriate detection. Our team often employs Competitive ELISA to detect and quantitate low molecular weight antigens, such as small molecule drug compounds (e.g., Gentamicin).

What are the critical applications of ELISA Method?

ELISA labs perform sensitive and selective quantitation of various antigens during drug discovery and development. We rely on ELISA method development to evaluate pharmacokinetics (PK) or anti-drug antibody (ADA) for novel biological treatments and determine biomarkers predictive of preclinical or clinical disease, therapeutic treatment, or toxicity adverse events. In summary, our ELISA labs and assay kit vendor ecosystem can be immensely advantageous to your bioanalytical method ELISA development and validation. For many of your drug R&D assays, we can optimize commercial ELISA kits for performance, selectivity, sensitivity, and are adaptability to multiple biological sample matrices.

How do we perform ELISA method validation?

Enzyme-linked immunosorbent assay (ELISA) method validation should be fit for purpose and follow the FDA Bioanalytical Method Validation Guidance for Industry (May, 2018), specifically related to ligand binding assays (LBAs). Generally, ELISA method validation includes –

  • All applicable experiments for Stock Solutions, Reference Standards, Quality Controls, Calibration Curve, Minimum Required Dilution, Spike Recovery, etc
  • Six independent validation runs over multiple days for estimating Intraday and Intraday Accuracy and Precision
  • Applicable experiments for Method Selectivity, Specificity, Matrix Effect, Matrix Suppression, etc.
  • Process Stability experiments for Short-term Bench-Top, Freeze-Thaw, and Long-Term Cycles

How is ELISA method influenced by antibodies, blocking, diluents, washing, etc.?

ELISA Labs perform method development and validation for your analyte of interest as per assay requirements such as calibration range and limitations such as antibody pair affinity, minimum required dilution, observed background, etc. In sandwich ELISA methods, the antibodies selected for capture and detection must bind to two distinct epitopes of the antigen and work well to achieve the quantitative assay goals. Also, we must choose appropriate plate binding surfaces, assay blockers, and buffers for diluents and washing to suit the sample matrix and yield selective and sensitive quantitation. Furthermore, we need to carefully optimize antibody and sample concentration and incubation times for ELISA development and validation. For instance, in ELISA Peptide is important for mapping of epitopes or definition of protein interaction sites. Among other factors, our scientists pay close attention to signal-to-noise (SNR) ratio, false-positive due to endogenous compounds, interference from endogenous or exogenous compounds, substrate selection, etc., for enhancing your ELISA method’s sensitivity, selectivity, specificity, and dynamic range.

How is ELISA Quantification affected by plate readers, pipetting, and equipment handling by lab personnel?

ELISA quantitation, like any other highly sensitive bioanalytical quantitation, should be handled with care and precision. To begin with, we must review proper calibration and verification of instrumentation, pipettes, and other equipment before use. Next, we must intensively train all ELISA lab personnel in protocol reproducibility, pipetting techniques, and pipette tip handling to perform ELISA Development and Validation. Generally, ELISA analysis plate readouts and incubation steps are highly time-dependent. Thus, we must emphasize that plates must be analyzed quickly following the addition of substrate for any pre-reads or final reads after stopping the reaction. We can automate sample analysis for ELISA assay with liquid handlers, plate washers, and other robotics adaptable to 96- or 384-well plates.

What are the significant limitations of an ELISA method?

ELISA methods and enzyme immunoassays are valuable tools for analyzing large molecule antigens, proteins, and antibodies but are not suitable for all small molecules and alternate biomolecules. For proper execution, ELISA protein assay must include reasonable incubation times, appropriate binding of antibodies to the intended epitopes for capture and detection, compatible buffers, and a suitable level of plate washing. Furthermore, ELISA methods do not generally include an internal standard (IS) as in chromatographic assays. That said, we may use a visible dye in the plate reader’s detection range to track dilutions throughout the assay as a surrogate ELISA IS to verify that your ELISA Lab properly executes the assay steps and dilutions.

How long does an ELISA Testing Services take?

Generally, our ELISA lab can perform sample analysis from 2-to-4 96-well plates within a typical workday if we have ELISA method development and immunoassay validation completed already. That said, sample preparation can vary per the complexity of the biological matrix and ELISA analysis itself (e.g., tissues or whole cells vs. serum). Similarly, sample incubation times can vary, typically overnight or less. Our scientists closely monitor and control the incubation and readout times during ELISA Method Development and sample analysis for consistency in your ELISA immunoassay results. Since the ELISA assay readouts are enzyme-dependent, lab personnel should read plates in the optimal reaction time window as the signal can decay markedly over time.

How does the ELISA Assay Development for anti-drug antibodies work?

Our GLP ELISA lab regularly performs immunogenicity studies that look for the potential immune response to therapeutic agents as needed for clinical drug studies. A bridging enzyme linked immunoassay is one of the most common methods to test for the presence and quantification of these anti-drug antibodies (ADA). In this sandwich ELISA assay development, a biotinylated drug compound gets attached to the streptavidin coated ELISA plate, and another labeled drug compound gets utilized as a detection agent. Ultimately, the anti-drug antibody of interest bridges these drug compounds together. Among other antibodies, this ELISA method gets frequently used for IgG and IgM ADA detection.

Can ELISA method be used for quantitative purposes?

ELISA methods and other types of enzyme immunoassays are typically used to quantitate large molecules in biological matrices with excellent sensitivity and specificity. It can be quite challenging to develop an ELISA method for a novel biologic molecule in-house. Thus, you would be in the superb company of pioneering biotech to rely on our ELISA lab to characterize your drug pharmacokinetics or its correlation to pharmacodynamic responses related to efficacy or toxicity. Generally, proper ELISA lab method development offers versatility and utility for biomarker determinations in relation to disease states and disease treatment and modulation. As with any other quantitative bioanalytical method, ELISA assay should be fully validated or at least partially qualified before use as appropriate to your study objectives.

How do you use Research Use Only (RUO) ELISA quantification Kits?

Research use only (RUO) label indicates in vitro diagnostic (IVD) products that can be used in the laboratory research phase of development. RUO ELISA kits are helpful for early drug discovery or preliminary diagnostic testing analyses but are not yet fully validated for compliance under GLP or clinical regulations. Commercially available RUO kits for ELISA lab protocols are typically qualified to some degree to ensure specificity, accuracy, and precision. Still, we need to fully validate these kits for the stability of test articles and critical reagents, cross-reactivity, or matrix interference. RUO ELISA Quantification procedures can be validated if the need arises, typically for novel biologic therapeutics reaching the preclinical toxicology phase or for novel clinical biomarkers of disease or therapy.

How is Enzyme Linked Fluorescent Assay (ELFA) different from Enzyme Linked Immunosorbent Assay (ELISA)?

Enzyme linked fluorescent assay (ELFA) is a similar enzyme immunoassay that uses the same principles as the ELISA assay but differs in the sample detection method. We use a fluorogenic substrate for detection in the ELFA assay instead of the chromogenic substrates used in ELISA assays. In general, ELFA is more sensitive than ELISA, making it helpful in detecting antigen biomarkers in earlier time windows relative to exposure for diagnostic disease testing.

Explore More Expertise